- Previous Close
1.4400 - Open
1.4500 - Bid 1.4400 x 100
- Ask 1.4700 x 100
- Day's Range
1.4120 - 1.5000 - 52 Week Range
1.0320 - 18.3600 - Volume
35,778 - Avg. Volume
755,030 - Market Cap (intraday)
2.582M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-1.5400 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.50
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.
www.60degreespharma.comRecent News: SXTP
View More
Performance Overview: SXTP
Trailing total returns as of 9/6/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SXTP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SXTP
View MoreValuation Measures
Market Cap
2.55M
Enterprise Value
10.99M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.50
Price/Book (mrq)
--
Enterprise Value/Revenue
26.26
Enterprise Value/EBITDA
22.23
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-95.59%
Return on Equity (ttm)
--
Revenue (ttm)
441.25k
Net Income Avi to Common (ttm)
-1.81M
Diluted EPS (ttm)
-1.5400
Balance Sheet and Cash Flow
Total Cash (mrq)
1.58M
Total Debt/Equity (mrq)
5.32%
Levered Free Cash Flow (ttm)
-1.06M
Research Analysis: SXTP
View MoreCompany Insights: SXTP
SXTP does not have Company Insights